What Cafeton Treats: Main Uses and Benefits

The core therapeutic purpose of this medication is commonly used for managing acute vascular headaches. Cafeton is applied in addressing acute symptomatic episodes, generally when symptoms become more noticeable. It is considered relevant for conditions involving vascular headaches, specifically migraine attacks and cluster headaches. The medication is used to help with symptoms related to heightened physiological activity and physical discomfort. This provides support that helps ease the overall symptom burden by assisting with symptom management.

The primary therapeutic domains include management of acute episodes of severe migraine headaches, certain migraine variants, and histaminic cephalalgia. The medication is commonly used across conditions presenting with acute episodes where pain intensity creates noticeable functional strain and when previous symptomatic assistance has been insufficient. It helps address symptom clusters that interfere with daily functioning, offering symptomatic relief that helps patients cope more steadily with difficult, high-severity episodes.

“The application is relevant when supportive symptom management is appropriate during sudden, high-intensity episodes.”

Quick Fact: Supports management of Severe Vascular Headaches

The eligibility for using Cafeton (Ergotamine/Caffeine) is strictly defined by regulatory authorities and is highly restrictive, focusing on absolute contraindications based on cardiovascular function, organ health, and life stage.

Eligibility and Exclusion Status

Conditions Defining Non-Eligibility

Use is absolutely Contraindicated in patients presenting with the following conditions, as stated in regulatory labeling:

• Vascular/Cardiac Disease: Peripheral Vascular Disease, Coronary Heart Disease, or Uncontrolled Hypertension.
• Organ Function: Severe Impaired Hepatic Function (Liver Disease) or Severe Impaired Renal Function (Kidney Disease).
• Systemic Conditions: Severe systemic infection, such as Sepsis.

Additionally, the medicine is Contraindicated for use with concurrent potent CYP3A4 Inhibitors, as this combination elevates the risk of severe vasospasm and ischemia, a life-threatening complication.

The official interaction profile for Cafeton (Ergotamine/Caffeine) is structured around two primary risks: severe pharmacokinetic interaction and additive vasoconstriction.

Contraindicated Drug Combinations

Co-administration with several classes of drugs is strictly prohibited in regulatory documents due to the risk of acute ergot toxicity (ergotism), resulting from elevated plasma concentrations of Ergotamine.

• Potent CYP3A4 Inhibitors: This includes macrolide antibiotics (e.g., Clarithromycin, Erythromycin, Troleandomycin), HIV protease inhibitors (e.g., Ritonavir, Nelfinavir), and azole antifungals (e.g., Ketoconazole, Itraconazole). These agents reduce the clearance of Ergotamine.
• Other Vasoconstrictors: The combination with other agents that cause vasoconstriction is contraindicated due to the risk of enhanced vascular effects. This includes other ergot derivatives and 5-HT1 receptor agonists (Triptans).

Other Documented Interactions

Population-Specific Notes

The medication is formally contraindicated in patients with severe hepatic or renal impairment. This interaction-related restriction is in place because reduced organ function impairs the body's ability to clear the active components, increasing the risk of toxicity.

Cafeton acts as an inhibitor targeting the RANKL-RANK signaling axis, a central regulator of osteoclast formation and activity. The drug selectively binds reversibly to the V1 receptor located on the surface of osteoclast progenitor cells and mature osteoclasts. This interaction prevents the conformational change required for full receptor activation by its ligand. By blocking this activation, Cafeton arrests the osteoclastogenic cascade, an intracellular signaling pathway that requires NF-kappaB activation and subsequent upregulation of genes critical for cellular differentiation. Specifically, this inhibition modulates the downstream processes of cell fusion and survival signaling, preventing the formation of new, fully functional osteoclasts. The consequence of this molecular blockade is a marked suppression of osteoclast-mediated bone resorption. This cellular action diminishes the overall rate of bone matrix degradation, reducing the net resorptive potential within the bone microenvironment.

How to Use Cafeton

Cafeton (Ergotamine tartrate and Caffeine) is an antimigraine agent intended for intermittent, acute use to address specific episodes of vascular headache; it is not approved for chronic daily administration. The official guidelines for administration strictly define the route, initial dose, subsequent dose timing, and maximum limitations.

Administration Routes and Standard Dosing

The medication is available in two approved dosage forms, each with specific administration rules:

Procedural and Maximum Use Constraints

Official instructions mandate that administration should be initiated at the first sign of the acute episode. Subsequent dosing must adhere strictly to the established intervals to prevent excessive use. The guidelines establish rigid maximum limits that must not be exceeded:

• Maximum Dose per Attack: Limited to 6 tablets or 2 suppositories per episode.
• Maximum Weekly Dose: Total use must not exceed 10 tablets or 5 suppositories within any 7-day period.

This structure ensures the medicine is reserved for episodic, acute intervention within the established boundaries.

Research Evidence / Overview of Studies for Cafeton

Evidence for use in Acute Vascular Headaches

Research has explored the combination product for use in adults experiencing conditions characterized by acute or disruptive episodes, such as severe migraine attacks and related vascular headaches. Studies exploring the product were primarily Randomized Controlled Trials (RCTs), many of which were conducted decades ago, alongside systematic reviews that synthesize the older findings. Research examined outcomes related to patient-reported physical discomfort by monitoring the change in headache intensity (e.g., from severe to mild or none) within short time frames (e.g., two hours). The studies also monitored the time to return of headache and tracked the incidence of re-emergence of symptoms over defined time intervals, such as the following 24 hours.

Studies report how symptoms evolved in the observed populations, noting patterns observed in the studies regarding short-term symptom changes. Research highlights changes measured during the study period, with some trials describing the proportion of patients whose reported pain level reached a pain-free or pain-reduced state at defined time points. Studies monitored whether the combination product reached a pain-free state with the same frequency or speed as other agents included in comparative trials. Findings described in regulatory sources have indicated that results were mixed or inconsistent in these comparisons.

Limitations of Older Studies and Comparison to Placebo

The overall evidence quality varies across studies, largely due to the age of some core research. Many foundational trials antedate current industry standards and modern research criteria (such as those established by the International Headache Society). Studies compared the combination product with a placebo (inactive control) during research scenarios with increased symptom activity. Research describes patterns observed in the studies that were often distinct from those observed with placebo, according to the short-term outcomes measured. However, the evidence base is noted to be heterogeneous, and the reported findings for different forms of the medication were not perfectly consistent across all older studies.

Long-Term Evidence and Follow-up Duration

Research exploring short-term symptom changes is abundant, as most trials measured immediate outcomes during a single acute episode. However, follow-up durations were limited in most controlled studies. There is limited information for long-term outcomes regarding the patterns observed when this product is used over many months or years, including how symptom patterns evolved over time. Evidence derived from settings with varying symptom burdens provides context about episodic use, but the long-term effects are not fully established through dedicated, multi-year controlled trials that evaluate the consistency of outcomes.

Research in Special Populations and Subgroups

Research has explored the combination product primarily in the adult population (ages 18 to 65) presenting with conditions characterized by acute or disruptive episodes. Data for certain groups remain insufficient. For instance, official regulatory sources note that there is a lack of established evidence regarding the efficacy or appropriate use of this combination product in the pediatric population (children and adolescents). Similarly, sample sizes were modest in studies involving older adults (geriatric patients), and dedicated, controlled studies exploring outcomes in pregnant or nursing populations are not readily available in the evidence record.

Summary of Research Uncertainty and Evidence Gaps

The evidence highlights what is known—and what is still uncertain. The primary uncertainty lies in the modest sample sizes and the age of the methodology underpinning much of the available research. Evidence is limited regarding the consistency of findings across all available delivery forms (e.g., oral tablet versus suppository), and subgroup findings are uncertain for specific variants of vascular headaches. Furthermore, due to the acute-use design of most trials, the research provides context regarding response patterns over continuous or frequent use, as the long-term effects are not fully established by controlled studies.

Key Studies & References

1. Label: ERGOTAMINE TARTRATE AND CAFFEINE tablet, film coated - DailyMed
2. Ergotamine and Caffeine: MedlinePlus Drug Information
3. Ergotamine Alkaloids in the Acute Treatment of Migraines - International Headache Society (IHS)

Common questions about Cafeton (FAQ)

Q: Does Cafeton cause stomach problems or changes in appetite?

A: Official information describes nausea and vomiting as commonly reported side effects experienced by patients using this medicine. Less frequently, a continuing loss of appetite has been listed as a serious adverse effect of unknown incidence.

Q: Is Cafeton ever prescribed to older adults, and are there different considerations?

A: While safety and effectiveness are not fully established in older adults, official warnings note that people over the age of 65 may be more likely to experience decreased circulation in their arms and legs. This risk requires careful consideration regarding exposure to cold temperatures.

Q: What types of food or drink should be avoided while using Cafeton?

A: According to regulatory documents, grapefruit and grapefruit juice should be avoided because they may increase the level of the drug in the body. Furthermore, the use of tobacco or nicotine products is noted as being associated with an increased risk of serious side effects.

Q: Do research studies on Cafeton often look at side effects on the heart?

A: Official regulatory labeling documents list serious and clinically significant vascular events, such as myocardial infarction (heart attack) and stroke. The official product monograph describes the need for cardiovascular evaluation in patients with known risk factors for coronary artery disease.

Q: Are there descriptive warnings about Cafeton for people who drive or operate machinery?

A: Official product information notes that this medicine may cause dizziness as a side effect. For this reason, regulatory information suggests caution regarding driving, operating machinery, or performing activities that require full alertness until the personal effects of the drug are known.

Q: How long after starting Cafeton should someone generally expect to notice an effect?

A: Official clinical data indicates that the onset of action for the caffeine component is typically approximately 45 minutes to 1 hour after administration. The vascular effects generally diminish after about three to four hours.

Q: If I stop taking Cafeton, does the effect wear off immediately?

A: Abrupt discontinuation of the drug following prolonged or frequent use has been associated with the development of withdrawal symptoms. These symptoms may include the re-emergence of severe headaches, often referred to as rebound headaches.

Q: Do you feel Cafeton working right away?

A: Based on clinical data, the onset of action for the caffeine component is approximately 45 minutes to one hour. This indicates that the full effect may not be perceived immediately after administration.

Q: Is a headache a common side effect reported by patients taking Cafeton?

A: Headaches are not listed as a common side effect in the official product labeling. However, regulatory documents describe a risk of medication overuse headache, which is a type of headache caused by prolonged or excessive use of the drug.

Q: Can Cafeton cause a feeling of drowsiness or fatigue?

A: Official product information indicates that drowsiness has been reported as a rare side effect of the medication. Additionally, unusual tiredness or weakness has been reported, although the frequency of these effects is not known.

Q: Is it true that Cafeton can interact with common supplements like St. John's Wort?

A: St. John's Wort is a supplement known to affect the CYP3A4 enzyme system, which helps the body process many drugs, including this one. Any potential effect of St. John's Wort on the drug's metabolism is a recognized area of concern regarding drug-drug interactions.

Q: Can taking Cafeton affect how birth control pills work?

A: According to official regulatory information, use of this drug is associated with an increased risk of stroke in women who have migraines with aura and use combination oral contraceptives. Additionally, studies indicate that birth control pills may extend the half-life (processing time) of the caffeine component of the drug.

Q: Are there any known interactions between Cafeton and alcohol consumption?

A: Official patient information indicates that alcohol may increase the feeling of dizziness caused by the medication. Regulatory information notes that consuming alcohol may also be a factor that triggers or worsens a headache.

Q: Does Cafeton have any connection to changes in mood or sleep patterns?

A: Official regulatory sources document reports of restlessness and trouble sleeping as side effects. Furthermore, anxiety and nervousness have also been reported by some patients using the medication.

Q: How quickly is Cafeton cleared from the body?

A: According to clinical data, the elimination half-life (the time it takes for half of the drug to be processed and cleared) of the caffeine component is approximately three to seven hours. The pharmacokinetics (how the body handles the drug) of the ergotamine component are noted as complex.

Q: Is Cafeton a drug that can be stopped suddenly?

A: Abrupt discontinuation of the drug following prolonged or continuous use has been associated with withdrawal symptoms. This may include the development of a severe headache sometimes referred to as a rebound headache.

Q: Are there specific instructions for what to do if a dose of Cafeton is missed?

A: Regulatory guidelines do contain specific information regarding how to handle a missed dose of the drug. These guidelines address the necessary timing for taking the missed dose, or when it should be skipped.

Q: Does Cafeton contain any ingredients that cause allergic reactions?

A: Allergic reactions like localized swelling (edema) and itching have been reported with this medicine. Furthermore, the product may contain inactive ingredients, such as certain dyes, which can be known to cause allergic reactions in some sensitive individuals.

Q: Is it possible to become physically dependent on Cafeton?

A: According to regulatory documents, the drug may rarely cause abnormal drug-seeking behavior and is considered potentially habit-forming. Additionally, overuse can lead to a complication where headaches become worse, known as medication overuse headache.

Q: Does Cafeton have a specific classification (e.g., controlled substance) in official sources?

A: Official U.S. regulatory sources, such as those from the Drug Enforcement Administration (DEA), indicate that this medicine is not classified as a federally controlled substance.

How to Store and Dispose of Cafeton?

Storing and disposing of Cafeton must adhere strictly to the conditions specified in official regulatory labeling to maintain product quality and safety.

Storage Requirements

Disposal Instructions

• Unused Medicine: Any unused Cafeton or waste materials must be disposed of in accordance with the local requirements and regulations for pharmaceutical waste.
• General Rule: Do not dispose of this medicine in household trash or wastewater (such as pouring down a sink or toilet) unless specifically instructed to do so by a healthcare professional or regulatory body.